RVL Pharmaceuticals plc RVLP
0.03 +0.03
Day range unavailable
52-week range unavailable
Analyst view
Consensus: buy
Buy
Price target (mean) 3.20 +11247.5% upside
Now 0.0282
- Target (low)
- 1.60
- Target (mean)
- 3.20
- Target (high)
- 6.00
Ratings (-1m) 3 3 buy · 0 hold · 0 sell
- Strong buy0
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 3
- 2 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.08 | -0.11 – -0.06 | -0.16 | +50.0% | 7.88M | -21.4% | 2 |
| Next quarter | -0.09 | -0.11 – -0.06 | -0.18 | +50.0% | 10.58M | +7.9% | 2 |
| Current year | -0.52 | -0.57 – -0.46 | -0.58 | +10.3% | 37.28M | -25.0% | 2 |
| Next year | -0.30 | -0.42 – -0.19 | -0.52 | +42.3% | 53.81M | +44.3% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 30, 2023 | Barclays | Maintained | — | Overweight |
| Mar 20, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Oct 24, 2022 | Barclays | Maintained | — | Overweight |
| Dec 22, 2021 | HC Wainwright & Co. | Initiated | — | Buy |
| Sep 23, 2021 | Cantor Fitzgerald | Initiated | — | Overweight |
| Mar 16, 2021 | RBC Capital | Maintained | — | Outperform |
| Jul 9, 2020 | SVB Leerink | Maintained | — | Outperform |
| Jul 9, 2020 | SunTrust Robinson Humphrey | Maintained | — | Buy |
| Mar 5, 2020 | SVB Leerink | Initiated | — | Outperform |